The EndoBarrier™ Gastrointestinal Liner is a breakthrough treatment designed to help patients regain metabolic control of type 2 diabetes and obesity. Clinical trials to date, involving more than 300 patients, have demonstrated significant weight loss and diabetes improvement with the EndoBarrier, when combined with certain diet and lifestyle modifications. In the United States the significance of these improvements is being studied in advanced studies.
The EndoBarrier is placed in the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine and to delay the mixing of digestive enzymes with the food. Physicians believe that preventing food from coming into contact with the intestinal wall and delaying digestion until farther down the intestine alters the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery.
Discover the Endobarrier
The EndoBarrier, a non-surgical therapy, received European CE mark approval in December 2009 and GI Dynamics plans to begin commercializing the EndoBarrier in select markets later this year. The company is currently working with leading diabetes and obesity treatment centers in Europe to train and certify clinicians to use EndoBarrier therapy. To learn more about the EndoBarrier and find an EndoBarrier Center of Excellence, please contact info@gidynamics.com. The device is in advanced investigational studies in the United States.
